Author

Grace Collins

Institution: Friends of Cancer Research

Observed institutions: Lancaster University, Friends of Cancer Research

ORCID: 0000-0003-4114-5938

Observed ORCID: 0000-0003-4114-5938

OpenAlex ID: A5029249776

Homologous Recombination Deficiency: Concepts, Definitions, and Assays

2022 · Mark D Stewart, Diana Merino Vega, et al. · The Oncologist · 257

An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012–2022

2023 · Grace Collins, Brittany McKelvey, et al. · Clinical Cancer Research · 18

Designing a Library of Lived Experience for Mental Health: integrated realist synthesis and experience-based co-design study in UK mental health services

2024 · Paul Marshall, Fiona Lobban, et al. · BMJ Open · 7

Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies

2022 · Grace Collins, Mark Stewart, et al. · Clinical Cancer Research · 7

Expedited Development Programs at the Food and Drug Administration: Insights and Opportunities

2021 · Grace Collins, Mark Stewart, et al. · Therapeutic Innovation & Regulatory Science · 4

Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project

2026 · Hillary S. Andrews, Nevine Zariffa, et al. · The Journal of Liquid Biopsy · 2

A cross-national review of novel oncology approvals in the United States and China (2020-2025)

2026 · Grace Collins, Divita Pandita, et al. · Health Affairs Scholar · 1

An Evaluation of Novel Oncology Approvals with a PMR/C for Assessing Data in Racial and Ethnic Populations Underrepresented in Premarket Clinical Trials

2024 · Grace Collins, Hillary S. Andrews, et al. · Clinical Cancer Research · 1

Early Circulating Tumor DNA Dynamics Predict Overall Survival in Solid Tumors: A Landscape Assessment

2026 · Elena Levi-D’Ancona, Hillary S. Andrews, et al. · JCO oncology advances.

Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs

2026 · Hillary S Andrews, Raja Agnihotram, et al. · The Oncologist

Works count: 10

Citation count: 297

H-index: 4

I10-index: 2